Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Second quarter sales growth of consumer businesses, which include Consumer Health Care division housing products such as Listerine and Lubriderm, and Shaving Products division, which includes Schick, has been "slower than anticipated," firm tells analysts July 17. Consumer Health Care sales increased 1.7% to $608 mil., while shaving sales decreased 10% to $179 mil. Synergies resulting from acquisition of Warner-Lambert in June 2000 "continue to be larger and to come sooner than originally planned," firm says; Pfizer now expects full-year 2001 merger-related savings of about $1.3 bil., versus prior estimate of $1.2 bil. For 2002, firm anticipates at least $1.6 bil. in merger-related savings, largely from work force cuts, increased purchasing power and reduction of operating expenses. Consolidated second quarter sales up 10% to $7.69 bil., driven by strong Rx drug sales

You may also be interested in...

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Chart: Weekly Trademark Review -- Nov. 2, 2010

Weekly Trademark Review




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts